Abstract
Fifty-two previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon (rIFN) alpha-2 and chemotherapy or chemotherapy alone. Patients were treated with vincristine, melphalan, cyclophosphamide and prednisolone every 4-6 weeks. In the combined treatment arm rIFN was administered concurrently with chemotherapy as well as during chemotherapy free intervals. The combined regimen effected 17/21 (80.9%) responses as compared to 19/27 (70.4%) responses in VMCP treated patients. Addition of rIFN to chemotherapy did not enhance hematologic toxicity. These findings suggest a somewhat higher rate of objective response in the VPMC + rIFN group, although a significant improvement in median survival by adding rIFN to conventional first line polychemotherapy in myeloma patients has not yet been achieved.
| Original language | English |
|---|---|
| Pages (from-to) | 27-29 |
| Number of pages | 3 |
| Journal | Oncology Research and Treatment |
| Volume | 12 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1989 |
Fingerprint
Keywords
- Combinations treatment
- Interferon-alpha-2
- Multiples Myeloma
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma. / Preis, Peter; Scheithauer, W.; Fritz, E.; Zielinski, C.; Kuehrer, I.; Cortelezzi, A.; Polli, E.; Raldini, L.; Pirker, R.; Kriegisch, A.; Ludwig, H.
In: Oncology Research and Treatment, Vol. 12, No. 1, 1989, p. 27-29.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma
AU - Preis, Peter
AU - Scheithauer, W.
AU - Fritz, E.
AU - Zielinski, C.
AU - Kuehrer, I.
AU - Cortelezzi, A.
AU - Polli, E.
AU - Raldini, L.
AU - Pirker, R.
AU - Kriegisch, A.
AU - Ludwig, H.
PY - 1989
Y1 - 1989
N2 - Fifty-two previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon (rIFN) alpha-2 and chemotherapy or chemotherapy alone. Patients were treated with vincristine, melphalan, cyclophosphamide and prednisolone every 4-6 weeks. In the combined treatment arm rIFN was administered concurrently with chemotherapy as well as during chemotherapy free intervals. The combined regimen effected 17/21 (80.9%) responses as compared to 19/27 (70.4%) responses in VMCP treated patients. Addition of rIFN to chemotherapy did not enhance hematologic toxicity. These findings suggest a somewhat higher rate of objective response in the VPMC + rIFN group, although a significant improvement in median survival by adding rIFN to conventional first line polychemotherapy in myeloma patients has not yet been achieved.
AB - Fifty-two previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon (rIFN) alpha-2 and chemotherapy or chemotherapy alone. Patients were treated with vincristine, melphalan, cyclophosphamide and prednisolone every 4-6 weeks. In the combined treatment arm rIFN was administered concurrently with chemotherapy as well as during chemotherapy free intervals. The combined regimen effected 17/21 (80.9%) responses as compared to 19/27 (70.4%) responses in VMCP treated patients. Addition of rIFN to chemotherapy did not enhance hematologic toxicity. These findings suggest a somewhat higher rate of objective response in the VPMC + rIFN group, although a significant improvement in median survival by adding rIFN to conventional first line polychemotherapy in myeloma patients has not yet been achieved.
KW - Combinations treatment
KW - Interferon-alpha-2
KW - Multiples Myeloma
UR - http://www.scopus.com/inward/record.url?scp=0024587844&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024587844&partnerID=8YFLogxK
U2 - 10.1159/000216593
DO - 10.1159/000216593
M3 - Article
C2 - 2654788
AN - SCOPUS:0024587844
VL - 12
SP - 27
EP - 29
JO - Oncology Research and Treatment
JF - Oncology Research and Treatment
SN - 2296-5270
IS - 1
ER -